TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05898880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure
Description: In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants

Intervention type: OTHER
Group type: OTHER
Intervention: Acupressure by therapists
Description: In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No intervention will be made in the control group.
Study: NCT05220995

Intervention type: GENETIC
Intervention: protocol
Description: ovarian stimulation protocols on euploid rates were compared.

Intervention type: GENETIC
Intervention: protocol
Description: ovarian stimulation protocols on euploid rates were compared.
Study: NCT05898373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedicitumomab (Edisil, RC48）
Description: intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedicitumomab in combination with pyrrolizidine
Description: vedicitumomab in combination with pyrrolizidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 in combination with a platinum-based chemotherapeutic agent
Description: RC48 in combination with a platinum-based chemotherapeutic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 in combination with teraplizumab
Description: RC48 in combination with teraplizumab
Study: NCT05297760

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Polvac Grass+Rye
Description: Suspension of micro crystalline tyrosine with grass and rye pollen allergen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polvac Grass+Rye
Description: Suspension of micro crystalline tyrosine with grass and rye pollen allergen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.
Study: NCT05048472

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbott HIV-1/2 VL Point of care Device
Description: Point of care viral load monitoring
Study: NCT05357794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Given by Vein (IV)
Study: NCT06307600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-03 cell injection
Description: The patients in this intervention will use RD06-03 cell injection with 3 dose dose 1: 1×10\^5 CAR+ T Cells/kg dose 2: 3×10\^5 CAR+ T Cells/kg dose 3: 5×10\^5 CAR+ T Cells/kg Dosage form: IV injection Frequency of administration：1 time
Study: NCT06407440

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: There will be no interference ergonomics training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
Study: NCT06023108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology
Description: OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
Study: NCT05219812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BAY2395840
Description: Tablet, intake orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BAY2395840
Description: Tablet, intake orally.
Study: NCT05350917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug .
Study: NCT05552482

Intervention type: OTHER
Intervention: Identification of predictive factors
Description: Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group

Intervention type: OTHER
Intervention: Identification of predictive factors
Description: Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group
Study: NCT06442020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tadalafil (PDE5i)
Description: Tadalafil at a dose of 5mg/day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil (PDE5i)
Description: Tadalafil at a dose of 5mg/day
Study: NCT06153485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoO2
Description: Automated Titration of Oxygen (Auto-O2) using a closed-loop system in which the oxygen flow to the participant is continuously adjusted on the basis of pulse oximetry signals to maintain a target range of oxygen saturation to meet the participant's immediate needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FixedO2
Description: Fixed flow oxygen delivery administered using manual flow meters according to standard clinical procedures.
Study: NCT06486506

Intervention type: OTHER
Intervention: Analysis
Description: Analysis and review of imaging and clinical data
Study: NCT04968405

Intervention type: DEVICE
Group type: OTHER
Intervention: Catalyst CSR Total Shoulder System
Description: The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
Study: NCT06121973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational group
Description: Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
Study: NCT06446479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol Pill
Description: Dronabinol 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol Pill
Description: Dronabinol 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT05756634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination after Preterm Birth (CCAPB)
Description: For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Care Coordination after Preterm Birth (CCAPB)
Description: For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
Study: NCT06120465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Yoga classes
Study: NCT06521021

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AVOID
Description: Behavioral: Home food environment and grocery delivery (AVOID) Participants will receive coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices~Behavioral: WW Participants assigned to all arms will receive of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RESIST
Description: Behavioral: Inhibitory control training (RESIST) Participants assigned to RESIST will receive coaching (Zoom and/or email/text) and gamified inhibitory control training.~Behavioral: WW Participants assigned to all arms will receive coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
Study: NCT05421754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANNE Sleep
Description: ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
Study: NCT05741203

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: lung ultrasound
Study: NCT06023212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: stroke-physiological saline solution (SPSS)
Description: IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
Study: NCT04814537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Local Anesthetic Agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Local Anesthetic Agent
Study: NCT05745727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-115
Description: Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
Study: NCT05696340

Intervention type: OTHER
Intervention: semi-structured interview
Description: Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation.

Intervention type: OTHER
Intervention: semi-structured interview
Description: Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation.

Intervention type: OTHER
Intervention: semi-structured interview
Description: Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation.
Study: NCT05011461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Oil
Description: Almond Oil Pressed Cold

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Almond Oil
Description: Almond Oil Pressed Cold
Study: NCT05337722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFT 2.0
Description: The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFT 2.0
Description: The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
Study: NCT04541069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Communication and Emotional Skill Development (SCESD) module
Description: The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
Study: NCT05565547

Intervention type: DEVICE
Intervention: META
Description: The META device is used for a comprehensive ophthalmic examination.

Intervention type: DEVICE
Intervention: Commercial devices
Description: Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
Study: NCT05491889

Intervention type: BIOLOGICAL
Intervention: trans arterial chemoembolization
Description: trans arterial chemoembolization in patient with partial portal vein thrombosis
Study: NCT05688657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
Study: NCT05194488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Patients will receive low-level laser therapy on the temporomandibular joint disc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior repositioning appliance
Description: Patients will receive hard maxillary anterior repositioning appliance.
Study: NCT05227235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Telemedicine
Description: Clinical consultation with patient performed with 3D Telemedicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D Telemedicine
Description: Clinical consultation with patient performed with 2D Telemedicine as standard of care
Study: NCT04964388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: Diabetes medication
Study: NCT06362239

Intervention type: OTHER
Intervention: Study Surveys
Description: Participants will complete study surveys as their participation in the research study. Study staff will collect clinical and demographic information from the electronic medical records. The enrollment in this intervention will not be decided by research enrollment, but would naturally occur regardless of enrollment in the study.

Intervention type: OTHER
Intervention: Study Surveys
Description: Participants will complete study surveys as their participation in the research study. Study staff will collect clinical and demographic information from the electronic medical records. The enrollment in this intervention will not be decided by research enrollment, but would naturally occur regardless of enrollment in the study.
Study: NCT05453799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vudalimab
Description: Given IV
Study: NCT05357183

Intervention type: DRUG
Intervention: PEG-IFN
Description: PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
Study: NCT04210570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memsorb
Description: Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memsorb
Description: Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memsorb
Description: Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical granulate absorber
Description: Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemical granulate absorber
Description: Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemical granulate absorber
Description: Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
Study: NCT04966221

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI scan
Description: Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI scan
Description: Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI scan
Description: Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
Study: NCT05573360

Intervention type: OTHER
Group type: OTHER
Intervention: NGF5-A test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF5-A test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF5-A test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF5-A test formulation
Description: One drop of investigational product instilled on the eye

Intervention type: OTHER
Group type: OTHER
Intervention: NGF5-A test formulation
Description: One drop of investigational product instilled on the eye
Study: NCT05260021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirzepatide Dose 1
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide Dose 1
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide Dose 2
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06242795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline via nebulization
Description: Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
Study: NCT05335772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation and following Action Execution
Description: VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Landscape Observation and following Action Execution
Description: VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.